Lindsey Macfarlane is a Rheumatology/Immunology physician. OpenAlex indexes 65 publications with 2,790 citations (h-index 25).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Medical Center Dr
Lebanon, NH 037560001
Telephone
603-650-5000Provider last certified this registry record 18 Nov 2024.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20253 payments
- ABBVIE INC.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
32.2%Xanthine oxidase inhibitor18.4%Allopurinol100%Part D<11 patientsAlkaloid8.6%Colchicine100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
22%JAK inhibitor9.4%Rinvoq100%Part D<11 patientsFolate Analog Metabolic Inhibitor6.9%Methotrexate100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
18.4%Corticosteroid18.4%Prednisone100%Part D≥21 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2025–2026 per NIH RePORTER. The latest:
- Improving health outcomes in older patients with osteoarthritis and multimorbidity
Dartmouth-Hitchcock Clinic
FY2026$217,130P20GM161873
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- POS1388 PATHOGENIC CSPG4+ EXTRACELLULAR VESICLES PREDICT KNEE OSTEOARTHRITIS PROGRESSION
Annals of the Rheumatic Diseases
2025 - Genicular Artery Embolization as a Treatment for Osteoarthritis Related Knee Pain: A Systematic Review and Meta-analysis
CardioVascular and Interventional Radiology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”